Supernus Pharmaceuticals Reports Strong Q2 2024 Growth
Supernus Pharmaceuticals has reported a robust financial performance for the second quarter of 2024, showcasing significant growth in net sales and positive cash flow. The company’s key growth drivers, Qelbree and GOCOVRI, have effectively contributed to a substantial increase in both prescriptions and net sales.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
